Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, while foods high in insoluble fiber, processed meat, spicy foods, dairy, and ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback